ALARMING! Mansanguan.: "Cardiovascular Effects of Pfizer mRNA COVID-19 Vaccine in Adolescents"; Cardiovascular effects found in 29.24% of patients, ranges from tachycardia, palpitation, myocarditis

The most common cardiovascular effects were tachycardia (7.64%), shortness of breath (6.64%), palpitation (4.32%), chest pain (4.32%), and hypertension (3.99%). Seven participants (2.33%) exhibited at

Very concerning data! CDC and NIH and FDA must urgently pay attention to this pre-print study!!!

Pre-print, not yet peer-reviewed. Excellent prospective study design. n=314, lost 13, thus 301 is the final data set.

CDC and NIH and FDA should be warned that this study is key.

Thai teenagers 13 to 18 years old, cardiovascular outcomes. This is observational cohort study (prospective). The RCTs that underpinned the vaccines were very poor relative to this prospective study. Key that they looked at was troponin T and CK (creatine kinase). These 2 enzymes are seen elevated if the heart cells/muscle is damaged in a heart attack.

Key is they found cardiovascular effects in near 30% of the subjects. Abnormal ECG in 18%.

You have to understand that 1 patient out of approximately 300 with myopericarditis is disastrous, very serious. This is 0.33%. 2 patients with suspected pericarditis (0.66%). 4 patients with subclinical myocarditis (1.33%). Can result in cardiac arrest (sudden death). This is very serious for any exertion, exercise can cause serious arrythmias and potential cardiac death. Any suspected myocarditis, pericarditis, myopericarditis demands immediate rest.

SOURCE

“This study focuses on cardiovascular effects, particularly myocarditis and pericarditis events, after BNT162b2 mRNA COVID-19 vaccine injection in Thai adolescents. This prospective cohort study enrolled students from two schools aged 13–18 years who received the second dose of the BNT162b2 mRNA COVID-19 vaccine. Data including demographics, symptoms, vital signs, ECG, echocardiography and cardiac enzymes were collected at baseline, Day 3, Day 7, and Day 14 (optional) using case record forms.

We enrolled 314 participants; of these, 13 participants were lost to follow up, leaving 301 participants for analysis.

The most common cardiovascular effects were tachycardia (7.64%), shortness of breath (6.64%), palpitation (4.32%), chest pain (4.32%), and hypertension (3.99%). Seven participants (2.33%) exhibited at least one elevated cardiac biomarker or positive lab assessments. Cardiovascular effects were found in 29.24% of patients, ranging from tachycardia, palpitation, and myopericarditis. Myopericarditis was confirmed in one patient after vaccination. Two patients had suspected pericarditis and four patients had suspected subclinical myocarditis.

Conclusion: Cardiovascular effects in adolescents after BNT162b2 mRNA COVID-19 vaccination included tachycardia, palpitation, and myocarditis. The clinical presentation of myopericarditis after vaccination was usually mild, with all cases fully recovering within 14 days. Hence, adolescents receiving mRNA vaccines should be monitored for side effects.”